Tag: Olaparib

1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. 2. The progression-free survival benefit was greater in patients with BRCA-positive and homologous recombination deficiency (HRD) positive tumors. Evidence Rating Level: 1 (Excellent) Study Rundown: Due to the late diagnosis of advanced-stage ovarian cancer,...
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. 2. The progression-free survival benefit was greater in patients with BRCA-positive and homologous recombination deficiency (HRD) positive tumors. Evidence Rating Level: 1 (Excellent) Study Rundown: Due to the late diagnosis of advanced-stage...
1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared to placebo. 2. The majority of adverse events reported in the olaparib group were low-grade. Among high-grade adverse events, anemia and neutropenia were the most common. Evidence Rating Level: 1 (Excellent)       Study Rundown: Though...
1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared to placebo. 2. The majority of adverse events reported in the olaparib group were low-grade. Among high-grade adverse events, anemia and neutropenia were the most common. Evidence Rating Level: 1 (Excellent)       Study...
1. In this phase II trial, use of the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib showed a positive response in a subset of metastatic castration-resistant prostate cancer patients with DNA repair defects. 2. While olaparib treatment showed evidence of anti-tumour growth through PSA and circulating tumour-cell decrease, and radiologic...
1. Olaparib monotherapy was associated with prolonged tumor response rate in advanced BRCA1/2-associated breast, ovarian, pancreatic, and prostate cancers. 2. Olaparib was well tolerated with common adverse side effects including anemia, fatigue, nausea, and vomiting. Evidence Rating Level: 3 (Average) Study Rundown: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously demonstrated...